All In Biotech

BLA 019717 · Lilly

Humulin 70/30 Pen

Insulin Recombinant Human, Insulin Susp Isophane Recombinant Human · Injection · Insulin

Last checked: Nov 20, 2026Latest source record: Jun 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Apr 25, 1989

Approved uses

1

Original approval plus efficacy supplements

Registered trials

100

15 Phase 3, 0 recruiting

FAERS reports

16,106

10,597 serious, 1,307 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 17, 2026.

HUMULIN 70/30 is a fixed ratio insulin formulation indicated to improve glycemic control in adults with diabetes mellitus. HUMULIN ® 70/30 is a mixture of insulin isophane human, an intermediate-acting human insulin, and insulin human, a short-acting insulin human, indicated to improve glycemic control in adults with diabetes mellitus. ( 1 )

Mechanism: HUMULIN 70/30 lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 25, 1989 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • HUMULIN 70/30 PEN · INSULIN RECOMBINANT HUMAN 30 UNITS/ML; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN 70 UNITS/ML · INJECTABLE, INJECTION · Over-the-counter
  • HUMULIN 70/30 · INSULIN RECOMBINANT HUMAN 30 UNITS/ML; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN 70 UNITS/ML · INJECTABLE, INJECTION · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Recombinant Human" as an intervention, any sponsor and status, largest first.

All 100 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased3,691
  • blood glucose decreased1,150
  • drug ineffective1,038
  • incorrect dose administered753
  • hypoglycaemia689
  • nausea641
  • dyspnoea600
  • weight decreased594
  • visual impairment573
  • diarrhoea552
  • fall548
  • dizziness505

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004503
2005543
2006765
2007442
2008314
2009394
2010348
2011354
2012351
2013409
2014686
20152,902
2016616
2017457
2018745
2019764
2020744
2021806
2022956
2023874
2024866
2025779
2026488

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Humulin 70-30 (Insulin NPh Hum/Reg Insulin Hm)

2024 spending

$32.2M

Beneficiaries

50,475

231,983 claims

Per beneficiary

$638

$4.12 per unit

View as table
YearSpending
2020$152,201,343
2021$141,804,928
2022$128,578,244
2023$117,022,878
2024$32,225,668

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Eli Lilly · Also marketed as Humulin 70/30

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.